Interv Akut Kardiol. 2008;7(6):207-209

Current position of GP IIb/IIIa inhibitors

Ivo Varvařovský
Kardio-Troll, pracoviště invazivní kardiologie, Krajská nemocnice, Pardubice

Published: December 20, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I. Current position of GP IIb/IIIa inhibitors. Interv Akut Kardiol. 2008;7(6):207-209.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Varvařovský I. Inhibitory destičkových receptorů GP IIb/IIIa. In: Varvařovský I, Matějka J. Antitrombotická léčba akutních koronárních syndromů. Praha: Galén, 2008: 131-144.
    2. Topol EJ, Moliterno DJ, Herrmann HC. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-1894. Go to original source... Go to PubMed...
    3. Steinhubl SR, Talley JD, Braden GA. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD multicenter study. Circulation 2001; 103: 2572-2578. Go to original source... Go to PubMed...
    4. Batchelor WB, Tolleson TR, Huang Y. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes. The COMPARE trial. Circulation 2002; 106: 1470-1476. Go to original source... Go to PubMed...
    5. Gawaz M, Ruf A, Pogatsa-Murray G. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors. Thromb Haemost 2000; 83: 915-922. Go to original source... Go to PubMed...
    6. Chan AW, Moliterno DJ, Berger PB. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the TARGET. J Am Coll Cardiol 2003; 42: 1188-1195. Go to original source... Go to PubMed...
    7. Steinhubl SR, Ellis SG, Wolski K. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 2001; 103: 1403-1409. Go to original source... Go to PubMed...
    8. Steinhubl SR, Badimon JJ, Beatt DL. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007; 12: 113-122. Go to original source... Go to PubMed...
    9. Kastrati A, Mehilli J, Schuhlen H. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350: 232-238. Go to original source... Go to PubMed...
    10. Schoming A, Schmidt C, Dibra A. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pretreatment with clopidogrel. Eur Heart J 2005; 26: 1379-1384. Go to original source... Go to PubMed...
    11. Kastrati A, Mehilli J, Neumann FJ. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. The ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-1538. Go to original source... Go to PubMed...
    12. Ndrepepa G, Kastrati A, Mehilli J. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. Eur Heart J 2008; 29: 455-461. Go to original source... Go to PubMed...
    13. Pannu R, Andraws R. Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials. Crit Pathw Cardiol 2008; 7: 5-10. Go to original source... Go to PubMed...
    14. Gumina RJ, Yang EH, Sandhu GS. Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention. Mayo Clin Proc 2008; 83: 995-1001. Go to original source... Go to PubMed...
    15. De Luca G, Suryapranata H, Stone GW. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction. A meta-analysis of randomized trials. JAMA 2005; 293: 1759-1765. Go to original source... Go to PubMed...
    16. Ortolani P, Marzocchi A, Marrozzini C. Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J 2008; publikováno on-line 7. 11. 2008. Go to original source... Go to PubMed...
    17. Berger JS, Brown DL. Association of glycoprotein IIb/IIIa inhibitors and long-term survival following administration during percutaneous coronary intervention for acute myocardial infarction. J Thromb Thrombolysis 2006; 21: 229-234. Go to original source... Go to PubMed...
    18. Coons JC, Seybert AL, Saul MI. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention. Ann Pharmacother 2005; 39: 1621-1626. Go to original source... Go to PubMed...
    19. Gurm HS, Smith DE, Collins JS. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2008; 51: 529-535. Go to original source... Go to PubMed...
    20. Romagnoli E, Burzotta F, Trani C. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 2007; 23: 57-63. Go to original source... Go to PubMed...
    21. Thiele H, Schindler K, Friedenberger J. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2008; 118: 49-57. Go to original source... Go to PubMed...
    22. Gibson CM, Zorkun C, Kunadian V. Intracoronary administration of abciximab in ST-elevation myocardial infarction. Circulation 2008; 118: 6-8. Go to original source... Go to PubMed...
    23. Bassand JP, Hamm CW, Ardissino D. Guidelines for the diagnosis and treatment of non-STsegment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660. Go to original source... Go to PubMed...
    24. Silva MA, Donovan JI, Gandhi PJ. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? Vasc Health Risk Manag 2006; 2: 39-48. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.